EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieRandomisierte kontrollierte Studie

Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort

Hirotoshi Watanabe iD, Takeshi Morimoto iD, Masahiro Natsuaki, Ko Yamamoto iD, Yuki Obayashi iD, Ryusuke Nishikawa iD, Tomoya Kimura iD, Kazuaki Imada, Satoru Suwa iD, Tsuyoshi Isawa iD, Kenji Ando iD, Takanari Fujita iD und 18 weitere

Circulation: Cardiovascular Interventions · 2026-06 · 19 (6)

DOI: 10.1161/circinterventions.125.016280 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2026-06. Verfasst von Hirotoshi Watanabe und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hirakata Kohsai Hospital, Japan (H.W., Takeshi Kimura). Hauptthemen laut MEDLINE: Clopidogrel, Platelet Aggregation Inhibitors, Aspirin, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Clopidogrel may have ischemic benefit over aspirin as long-term monotherapy in patients receiving percutaneous coronary intervention. METHODS: Both the STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy-2) and STOPDAPT-2 ACS (Short and Optimal Duration of Dual Antiplatelet Therapy-2 Study for the Patients With Acute Coronary Syndrome) were multicenter, open-label, adjudicator-blinded, randomized clinical trials in Japan, with the same protocol except that the STOPDAPT-2 ACS enrolled patients with acute coronary syndrome, exclusively. The patients after percutaneous coronary intervention with cobalt-chromium everolimus-eluting stents were randomized into 1-month dual antiplatelet therapy followed by clopidogrel monotherapy (clopidogrel group) or 12-month dual antiplatelet therapy followed by aspirin monotherapy (aspirin group). Follow-up duration was 5 years. The clinical effect between clopidogrel and aspirin monotherapy was compared by the 1-year landmark analysis in the STOPDAPT-2 ACS and STOPDAPT-2 total cohort, a pooled cohort of the 2 trials. The primary end point was the composite of cardiovascular end point (cardiovascular death, myocardial infarction, stroke, or definite stent thrombosis) and bleeding end point (Thrombolysis in Myocardial Infarction major/minor). The major secondary end points were each of the cardiovascular composite end point and the bleeding end point. RESULTS: Of 2986 patients (clopidogrel group: 1492, aspirin group: 1494) in the 5-year analysis of the STOPDAPT-2 ACS, 2875 (96.3%) completed follow-up. By the 1-year landmark analysis, clopidogrel group was superior to aspirin group for both the primary end point (6.18% and 8.27%; hazard ratio, 0.75 [95% CI, 0.57–0.997]; P =0.048) and the major secondary cardiovascular end point (4.73% and 6.77%; hazard ratio, 0.70 [95% CI, 0.51–0.96]; P =0.03). In the STOPDAPT-2 total cohort, including 5991 patients, the superiority of clopidogrel over aspirin for the cardiovascular end point was highly significant (hazard ratio, 0.74 [95% CI, 0.60–0.91]; P =0.004), although the superiority on the primary end point was insignificant (hazard ratio, 0.86 [95% CI, 0.72–1.03]; P =0.11). There was no between-groups difference in the major secondary bleeding end point, both in the STOPDAPT-2 ACS and STOPDAPT-2 total cohort. CONCLUSIONS: Clopidogrel monotherapy was superior to aspirin monotherapy for cardiovascular outcomes beyond 1 year after percutaneous coronary intervention, without increased bleeding risk. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02619760 and NCT03462498.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClopidogrelPlatelet Aggregation InhibitorsAspirinPercutaneous Coronary InterventionAcute Coronary SyndromeDual Anti-Platelet TherapyHumansTime FactorsTreatment OutcomeHemorrhageAgedMaleDrug-Eluting StentsFemaleMiddle AgedRisk FactorsJapanCoronary ThrombosisMyocardial InfarctionDrug Administration ScheduleChromium Alloys

Stichwörter der Autor:innen

aspirinclopidogreleverolimusmyocardial infarctionthrombosis

Substanzen

ClopidogrelPlatelet Aggregation InhibitorsAspirinChromium Alloys

Autor:innen und Institutionen

  • Department of Cardiology, Hirakata Kohsai Hospital, Japan (H.W., Takeshi Kimura).
  • Department of Data Science, Hyogo Medical University, Nishinomiya, Japan (T.M.).
  • Department of Cardiovascular Medicine, Saga University, Japan (M.N.).
  • Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan (K.Y., K.A.).
  • Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Japan (Y. Obayashi, R.N., K.I., K.O.).
  • Department of Cardiology, Mitsubishi Kyoto Hospital, Japan (Tomoya Kimura).

ORCID-Profile: Hirotoshi Watanabe, Takeshi Morimoto, Ko Yamamoto, Yuki Obayashi, Ryusuke Nishikawa, Tomoya Kimura, Satoru Suwa, Tsuyoshi Isawa, Kenji Ando, Takanari Fujita, Kazushige Kadota, Hiroki Sakamoto, Kohei Wakabayashi, Koh Ono, Fujio Hayashi, Kengo Tanabe, Masaharu Akao, Yuko Onishi, Ruka Yoshida, Toshihiro Tamura, Masahiro Yagi, Takeshi Kimura

Zitieren

APA

Watanabe, H., Morimoto, T., Natsuaki, M., Yamamoto, K., Obayashi, Y., Nishikawa, R., Kimura, T., Imada, K., Suwa, S., Isawa, T., Ando, K., Fujita, T., Kadota, K., Tokuyama, H., Sakamoto, H., Suzuki, H., Wakabayashi, K., Ono, K., Hayashi, F., …, & STOPDAPT-2 ACS investigators (2026). Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort. Circulation: Cardiovascular Interventions, 19(6). https://doi.org/10.1161/circinterventions.125.016280

Vancouver

Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Nishikawa R, et al. Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort. Circulation: Cardiovascular Interventions. 2026;19(6). doi:10.1161/circinterventions.125.016280

BibTeX
@article{Watanabe2026,
  author = {Watanabe, Hirotoshi and Morimoto, Takeshi and Natsuaki, Masahiro and Yamamoto, Ko and Obayashi, Yuki and Nishikawa, Ryusuke and Kimura, Tomoya and Imada, Kazuaki and Suwa, Satoru and Isawa, Tsuyoshi and Ando, Kenji and Fujita, Takanari and Kadota, Kazushige and Tokuyama, Hideo and Sakamoto, Hiroki and Suzuki, Hiroshi and Wakabayashi, Kohei and Ono, Koh and Hayashi, Fujio and Tanabe, Kengo and Akao, Masaharu and Onishi, Yuko and Yoshida, Ruka and Kusuyama, Takanori and Tamura, Toshihiro and Onoue, Yoshiro and Yagi, Masahiro and Kaitani, Kazuaki and Kimura, Takeshi and STOPDAPT-2 ACS investigators, STOPDAPT-2 ACS investigators},
  title = {Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2026},
  volume = {19},
  number = {6},
  doi = {10.1161/circinterventions.125.016280}
}
Kostenlos starten →